EYEN logo

Eyenovia (EYEN) Company Overview

Profile

Full Name:

Eyenovia, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 25, 2018

Indexes:

Not included

Description:

Eyenovia is a biotechnology company focused on developing innovative eye care treatments. They use a unique delivery system to improve the effectiveness of medications for eye diseases. Their goal is to enhance patient outcomes and make eye treatments easier and more effective for doctors and patients.

Events Calendar

Earnings

Next earnings date:

Mar 18, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 3, 2025

Analyst ratings

Recent major analysts updates

Nov 18, 24 Ladenburg Thalmann
Neutral
Nov 18, 24 HC Wainwright & Co.
Neutral
Nov 15, 24 William Blair
Market Perform
Nov 15, 24 Brookline Capital
Hold
Nov 13, 24 HC Wainwright & Co.
Buy
Aug 13, 24 HC Wainwright & Co.
Buy
Jul 24, 24 HC Wainwright & Co.
Buy
May 16, 24 HC Wainwright & Co.
Buy
Mar 19, 24 HC Wainwright & Co.
Buy
Mar 6, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
EYEN
globenewswire.comFebruary 5, 2025

Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization

Eyenovia Announces 1-for-80 Reverse Stock Split
Eyenovia Announces 1-for-80 Reverse Stock Split
Eyenovia Announces 1-for-80 Reverse Stock Split
EYEN
globenewswire.comJanuary 28, 2025

Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
EYEN
globenewswire.comJanuary 15, 2025

Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
EYEN
globenewswire.comJanuary 6, 2025

Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60%

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
EYEN
globenewswire.comDecember 6, 2024

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”),  an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company's stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions.

Eyenovia Provides Update on Restructuring Efforts
Eyenovia Provides Update on Restructuring Efforts
Eyenovia Provides Update on Restructuring Efforts
EYEN
globenewswire.comNovember 22, 2024

Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
EYEN
zacks.comNovember 18, 2024

EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
EYEN
benzinga.comNovember 15, 2024

On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.

Eyenovia Provides Update on Phase 3 CHAPERONE Study
Eyenovia Provides Update on Phase 3 CHAPERONE Study
Eyenovia Provides Update on Phase 3 CHAPERONE Study
EYEN
globenewswire.comNovember 15, 2024

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
EYEN
globenewswire.comOctober 16, 2024

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery

FAQ

  • What is the ticker symbol for Eyenovia?
  • Does Eyenovia pay dividends?
  • What sector is Eyenovia in?
  • What industry is Eyenovia in?
  • What country is Eyenovia based in?
  • When did Eyenovia go public?
  • Is Eyenovia in the S&P 500?
  • Is Eyenovia in the NASDAQ 100?
  • Is Eyenovia in the Dow Jones?
  • When was Eyenovia's last earnings report?
  • When does Eyenovia report earnings?
  • Should I buy Eyenovia stock now?

What is the ticker symbol for Eyenovia?

The ticker symbol for Eyenovia is NASDAQ:EYEN

Does Eyenovia pay dividends?

No, Eyenovia does not pay dividends

What sector is Eyenovia in?

Eyenovia is in the Healthcare sector

What industry is Eyenovia in?

Eyenovia is in the Biotechnology industry

What country is Eyenovia based in?

Eyenovia is headquartered in United States

When did Eyenovia go public?

Eyenovia's initial public offering (IPO) was on January 25, 2018

Is Eyenovia in the S&P 500?

No, Eyenovia is not included in the S&P 500 index

Is Eyenovia in the NASDAQ 100?

No, Eyenovia is not included in the NASDAQ 100 index

Is Eyenovia in the Dow Jones?

No, Eyenovia is not included in the Dow Jones index

When was Eyenovia's last earnings report?

Eyenovia's most recent earnings report was on Nov 12, 2024

When does Eyenovia report earnings?

The next expected earnings date for Eyenovia is Mar 18, 2025

Should I buy Eyenovia stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions